GSK
Stock Details
GSK is GSK plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 44.00$. Average daily volumn in 3 months 5.66M. Market cap 111.06B
Stock symbol : GSK. Exchange : NYSE. Currency : USD Lastest price : 43.69$. Total volume : 3.94M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
GSK plc (GSK)
Last Price
43.69$Change
0.94Volume
3.94M
| Previous Close | 42.75 |
| Open | 43.29 |
| Day Range | 43.00-43.70 |
| Bid | 43.43 x 1.8k |
| Ask | 43.60 x 3.1k |
| Volume | 3.94M |
| Average Volume | 5.66M |
| Market Cap | 111.06B |
| Beta | 0.29 |
| 52 Week Range | 37.80-46.97 |
| Trailing P/E | 17.69 |
| Foward P/E | 12.48 |
| Dividend (Yield %) | 4.55% |
| Ex-Dividend Date | 2022-05-19 |
Financial Details
Organization
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory... , HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Market Cap:
111.06BRevenue:
34.11BTotal Assets:
79.1BTotal Cash:
4.27B
News about "GSK plc"
Brookstone Capital Management Sells 25,049 Shares of GSK plc (NYSE:GSK)
Source from : Defense World - 10 hours ago
Brookstone Capital Management decreased its holdings in shares of GSK plc (NYSE:GSK – Get Rating) by 55.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 20,081 ...See details»
GSK plc (LON:GSK) Insider Acquires £10,940.77 in Stock
Source from : Defense World - 16 hours ago
GSK plc (LON:GSK – Get Rating) insider Manvinder Singh Banga bought 647 shares of the firm’s stock in a transaction on Thursday, June 23rd. The stock was bought at an average cost of GBX 1,691 ($20.71 ...See details»
Sanofi-GSK first to report a successful efficacy study against Omicron with Covid-19 Beta-containing vaccine
Source from : Pharmabiz - 15 hours ago
Sanofi-GSK first to report a successful efficacy study against Omicron with Covid-19 Beta-containing vaccine: London, UK Saturday, June 25, 2022, 11:00 Hrs [IST] GSK plc and Sanof ...See details»
A Lesson to Learn: GSK plc (GSK)
Source from : newsheater - 2 days ago
GSK plc (NYSE:GSK) went up by 0.48% from its latest closing price compared to the recent 1-year high of $46.97. The company’s stock price has collected 1.77% of gains in the last five trading sessions ...See details»
Covid-19 Variant Shot From Sanofi, GSK Effective Against Omicron
Source from : Wall Street Journal - 1 days ago
The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.See details»
Sanofi-GSK Reports Positive Data From COVID-19 Beta-containing Vaccine Trial
Source from : Nasdaq - 1 days ago
Drug majors Sanofi (SNYNF, SNY) and GSK plc (GSK.L) announced Friday positive data from their vaccine trial which evaluated an adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. Sanofi-GSK ...See details»
Waiting for a GSK Mega Deal Hurts Like Toothache
Source from : Washington Post - 2 days ago
Reckitt would be a logical buyer for GSK’s consumer health spinoff Haleon. But the consumer goods giant should be in no rush.See details»
GSK says its drug for chronic hep B could ‘lead to a functional cure’ — but will it be alone or in combination?
Source from : ENDPOINTS NEWS - 8 hours ago
GSK, newly branded and soon-to-be demerged, shared interim results from its Phase II trial on its chronic hepatitis B treatment, one that it says has the “potential to lead to a functional cure.” At a ...See details»
GSK plc (NYSE: GSK): Is Its Value Too High Compared To Others?
Source from : stocksregister - 22 days ago
GSK plc (NYSE:GSK) shares, rose in value on Friday, June 03, with the stock price down by -1.06% to the previous day’s close as strong demand from buyers drove the stock to $42.93. Actively observing ...See details»
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Source from : YAHOO!Finance - 1 days ago
Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the ...See details»
GSK plc (GSK) upgraded Issued by Wall Street Gurus
Source from : newsheater - 12 days ago
GSK plc (NYSE:GSK) went up by 1.77% from its latest closing price compared to the recent 1-year high of $46.97. The company’s stock price has collected 2.53% of gains in the last five trading sessions ...See details»
GSK to Invest GBP1 Bln Tackling Infectious Diseases in Low-Income Countries
Source from : MarketWatch - 2 days ago
By Joe Hoppe GSK PLC said Thursday that it will invest 1 billion pounds ($1.23 billion) to accelerate research and development over the next 10 ...See details»
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
Source from : Zacks.com on MSN.com - 12 days ago
GSK plc GSK announced positive headline data from a pre-specified efficacy interim analysis of the phase III study — AReSVi 006 — evaluating its respiratory syncytial virus (RSV) vaccine candidate for ...See details»
Promising hep B data helps GSK inch closer to functional cure
Source from : KFGO - 8 hours ago
An interim analysis of GSK’s experimental hepatitis B therapy bepirovirsen in a mid-stage study has raised hopes for a functional cure for millions suffering from a chronic infection, the British ...See details»